Dr. Andrew Muddle, Cofounder and CEO of MedPharm, told Outsourcing-Pharma.com that the company wanted to give “an even better service” to its customers.
Currently, he explained more than 50% of the company’s business revenue is from US-based clients.
“With the new labs we believe this percentage will increase,” he said, adding that MedPharm has seen the most demand from large and small dermatology companies.
“Significant contracts are being negotiated which are validating our decision to open US laboratory facilities,” Muddle said.
The new facility will offer performance testing for topical and transdermal products. Specifically, performance testing including skin (and other mucus membranes) penetration studies and biological testing on dermatology skin disease models, Muddle explained.